Brand Name

Vraylar

Generic Name
Cariprazine
View Brand Information
FDA approval date: September 17, 2015
Classification: Atypical Antipsychotic
Form: Kit, Capsule

What is Vraylar (Cariprazine)?

VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 1.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder

Summary: Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Gi...

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

Summary: The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.